Early Alzheimer’s Progressed at the Same Pace on Oral Semaglutide

CATEGORY: BRAIN & MENTAL HEALTH

Two years of a daily semaglutide tablet did not slow early Alzheimer’s disease. This is the same compound sold by injection for type 2 diabetes and weight loss. Across two large randomized trials enrolling 3,808 people, scores on an 18-point dementia rating scale worsened by roughly two points whether participants took the drug or a placebo. The difference between the groups came to about a tenth of a point or less in both trials, well inside the range of chance. The results were published together in The Lancet.¹

Two Trials, Forty Countries, One Tablet a Day

The trials are named evoke and evoke+. They enrolled adults aged 55 to 85 with mild cognitive impairment or mild dementia due to Alzheimer’s disease, confirmed by testing for amyloid, the sticky protein that accumulates in Alzheimer’s brains. One trial had 1,855 participants and the other 1,953, at sites in about 40 countries. Allocation to a once-daily 14 mg tablet or an identical placebo was random, and neither the participants nor the staff knew who was getting which. Treatment ran 104 weeks. The main outcome was the Clinical Dementia Rating, sum-of-boxes version: a structured interview with the participant and someone who knows them well, scoring memory, orientation, judgment, community activities, home life and personal care into a single 18-point total, where higher means worse.

A Tenth of a Point Between Drug and Placebo

In evoke, scores worsened by 2.3 points in both groups, a difference of 0.08 points between semaglutide and placebo. In evoke+, scores worsened 2.2 points with semaglutide and 2.1 with placebo, a difference of 0.10 points. Among participants who began with mild cognitive impairment, the drug also did not meaningfully change how many went on to dementia. The tablet was not sitting idle. People on semaglutide lost 5.8% of their body weight on average while the placebo group gained slightly, and side effects, mostly nausea, reduced appetite and other stomach complaints, matched the drug’s familiar profile. The medication was doing its known metabolic work. It simply was not slowing Alzheimer’s.

Why Researchers Expected More

The trials were launched on a promising trail of clues. Studies following large populations had found that people taking GLP-1 drugs, the class that mimics a gut hormone to curb appetite and steady blood sugar, went on to be diagnosed with dementia less often, up to 64% less in some analyses, and a smaller trial of the related drug liraglutide had hinted at preserved brain volume.² But people who take these medications differ from people who do not in weight, health care and dozens of other ways, and following people’s own choices cannot untangle the drug from the person. A randomized comparison can, and the association did not survive it. A biological substudy sharpened the puzzle. In the spinal fluid of 199 participants, levels of tau, a protein tied to Alzheimer’s damage, ran roughly 10% lower on semaglutide, and an inflammation marker in the blood fell substantially, yet the visible course of the disease did not change.¹ The drug behaved like a cleanup crew sweeping debris from a building that keeps settling at the same rate.

What the Verdict Closes, and What Stays Open

These trials tested one thing: whether semaglutide could slow Alzheimer’s disease that had already begun, over two years, in people with confirmed disease. The answer came back clear enough that a planned third year was discontinued. Nothing here bears on the drug’s established benefits for diabetes, obesity and heart disease, which rest on their own trials. Whether GLP-1 drugs might matter much earlier, before symptoms appear, was not tested. Alzheimer’s researchers have noted that decisive negative trials like these redirect a field’s effort rather than end it.

Key Takeaways

• Two randomized trials enrolling 3,808 people with early Alzheimer’s disease found no slowing of decline from a daily oral semaglutide tablet. Drug and placebo groups both worsened by roughly two points on an 18-point scale over two years.
• The trials were run because population studies had linked GLP-1 drugs to less dementia. The randomized comparison did not confirm a treatment effect, a reminder that association is not causation.
• Alzheimer’s-related proteins fell modestly in a spinal-fluid substudy, but that biological change did not translate into slower memory or functional decline. What was tested was treatment of existing early disease, not prevention in people without symptoms.

References

1. Cummings JL, Atri A, Sano M, et al. Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer’s disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials. The Lancet. 2026;407(10544):2167–2179. link
2. Cummings J, Atri A, Feldman HH, et al. evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimer’s disease. Alzheimer’s Research & Therapy. 2025;17(1):14. link